BioNeex Interview with EVP, Head of Oncology at CHBC, Dr. Jeffrey Bockman discussing Cancer Progress

Cello Health BioConsulting (CHBC), previously Defined Health, is hosting the 30th annual Cancer Progress conference, the premier cancer conference for industry leaders on May 7-8, 2019 in New York City. BioNeex as a partner company of Cello Health BioConsulting is supporting the Cancer Progress. To register to Cancer Progress please visit: https://www.cancerprogressbydh.com/registration/. About Cancer Progress Since 1989, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference. The 30th Annual Meeting on May 7-8, 2019 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference. https://www.cancerprogressbydh.com About Cello Health BioConsulting Cello Health BioConsulting, previously Defined Health, founded more than 25 years ago, is a leading biopharmaceutical business development strategy consulting firm whose clients include a mix of pharma, biotech and specialty pharmaceutical companies. Cello Health BioConsulting's consultants hold advanced degrees in science, medicine and business, and have industry experience in business development, commercial evaluation, finance, licensing, drug discovery and R&D. https://www.cellohealthbioconsulting.com About BioNeex BioNeex is an online, peer-to-peer platform for R&D-stage licensing and collaborative partnerships in the biopharmaceutical industry. In other words, BioNeex provides a user-friendly infrastructure for preclinical and clinical stage biotech companies to display their novel compounds available for licensing and co-development partnerships on a global scale. On the other hand, the platform offers pharmaceutical companies a direct access to such innovative compounds, which will enable them to fill their R&D pipeline. https://www.bioneex.com